Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 1,301–1,400 of 4,108
Osteoporosis treatment disparities: a 6-year aggregate analysis from national survey data
Cunningham, T. D., Pace, B. S. D., & Ullal, J. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2747-9 · Cited by 18
An Evaluation of the Use of Oral Bisphosphonates and Risk of Esophageal Cancer
Haber, S. L., & McNatty, D. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q482 · Cited by 18
Edwards, B. J.-A. (2017) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2017.06.024 · Cited by 18
Leslie, W. D., Majumdar, S. R., Morin, S. N., Lix, L. M., Schousboe, J. T., Ensrud, K. E., Johansson, H., McCloskey, E. V., & Kanis, J. А. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4415-y · Cited by 19
Ronis, M. J. J., Watt, J. D., Pulliam, C. F., Williams, A. E., Alund, A. W., Haque, E., Gadupudi, G. S., & Robertson, L. W. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02645-w · Cited by 18
Therapeutic targeting of Wnt antagonists by small molecules for treatment of osteoporosis
Shah, A. A., Chand, D., Ahamad, S., Porwal, K., Chourasia, M. K., Mohanan, K., Srivastava, K. R., & Chattopadhyay, N. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116587 · Cited by 22
Rethinking Vitamin D Deficiency: Controversies and Practical Guidance for Clinical Management
Henríquez, M. S., Suau, Ó. T., Romero, M. G. D. T., Hidalgo, M. J. C., Tarazona‐Santabalbina, F. J., Etxebarría-Foronda, Í., Diaz‐Guerra, G. M., & Valdés-Llorca, C. (2025) · Nutrients · doi:10.3390/nu17223573 · Cited by 24
“Other experts and societies recommend daily doses of up to 2000 IU for this population [54,103,117], especially in patients with osteoporosis, fractured or institutionalized older adults [118].”
The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton
Gingery, A., Subramaniam, M., Pitel, K. S., Reese, J. M., Cicek, M., Lindenmaier, L. B., Ingle, J. N., Goetz, M. P., Turner, R. T., Iwaniec, U. T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098219 · Cited by 18
Hubbard, L. D., & Mayre-Chilton, K. M. (2018) · Clinical Case Reports · doi:10.1002/ccr3.1898 · Cited by 16
Kim, T. J., & Koo, K. C. (2020) · Cancers · doi:10.3390/cancers12061529 · Cited by 24
“Such evaluations include neurological examination and a thorough assessment of prescription medications for side effects that could affect balance [85].”
BackgroundKanakis, A. S., Vipperla, K., Papachristou, G. I., Brand, R. E., Slivka, A., Whitcomb, D. C., & Yadav, D. K. (2020) · Pancreatology · doi:10.1016/j.pan.2020.07.396 · Cited by 21
Xiao, X., & Wu, Q. F. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00809-4 · Cited by 17
Recommandations françaises de la prise en charge et du traitement de l’ostéoporose masculine
Bouvard, B., Briot, K., Legrand, É., Blain, H., Breuil, V., Chapurlat, R. D., Duquenne, M., Guggenbuhl, P., Lespessailles, É., Thomas, T., et al. (2021) · Revue du Rhumatisme · doi:10.1016/j.rhum.2021.02.024 · Cited by 24
“…chronique obstructive. l P r En tenant compte de ces données et des recommandations de la plupart des organisations internationales (IOF, NOF [12], ISCD), nous recommandons de rechercher les facteurs de risque d’ostéoporose chez l’homme après 70 ans et de mesurer la densité minérale osseuse…”
Osteoporosis Screening Is Often Indicated but Overlooked Prior to Rotator Cuff Repair
Cotter, E. J., Klosterman, E. L., Winzenried, A. E., Greiner, J. J., & Grogan, B. F. (2021) · Arthroscopy Sports Medicine and Rehabilitation · doi:10.1016/j.asmr.2021.01.002 · Cited by 21
“National Osteoporosis Foundation (NOF) guidelines have included fragility fractures and fracture risk as estimated using the Fracture Risk Assessment Tool (FRAX)(22) to define indications for pharmacologic treatment.(23) To date, a paucity of literature exists examining whether patients undergoing RCR are being approp…”
BackgroundMethodInfluentialDieckmeyer, M., Rayudu, N. M., Yeung, L. Y., Löffler, M. T., Sekuboyina, A., Burian, E., Sollmann, N., Kirschke, J. S., Baum, T. H., & Subburaj, K. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.109827 · Cited by 19
Shu, L.-Y., Fu, Y., & Sun, H. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17457 · Cited by 18
“From the included articles, two independently authors extracted the following information: (1) name of the first author and publication year; (2) country; (3) basic characteristics of individuals including sample size, mean age, mean BMI, and mean time since menopause; (4) details of biochemical examination including…”
BackgroundMethodChang, E., Nickel, B. T., Binkley, N., Bernatz, J. T., Krueger, D. C., Winzenried, A. E., & Anderson, P. A. (2022) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/21514593221116413 · Cited by 18
“However, this includes only hip and spine fractures.(18) A modified version of the clinical osteoporosis criteria was developed in this study to create a more functional and clinically applicable definition that an orthopedic provider could use to assess a patient’s bone health without the need for BMD.”
BackgroundMethodLee, K., Kim, H., & Kim, H. (2023) · Medicine · doi:10.1097/md.0000000000032580 · Cited by 17
“5), FRAX-MOF ≥ 20%, or FRAX-HF ≥ 3%.[22] A recent study also reported that FRAX and TBS-adjusted FRAX in patients with SSc did not result in any new indications for therapeutic intervention.”
BackgroundA summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis
Belaya, Z. E., Rozhinskaya, L. Y., Dedov, I. I., Drapkina, O. M., Fadeev, V. V., Golounina, O. O., Lesnyak, O. M., Mamedova, E., Mel'nichenko, G. A., Petraikin, A. V., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-022-06667-6 · Cited by 24
“If osteoporotic fractures are not detected during the initial patient assessment or spinal X-ray, the decision on the need for osteoporosis therapy is made based on the 10-year probability of major osteoporotic fracture calculated using FRAX [1, 12, 50, 51].”
MethodZhang, Z., Sun, Z., Jia, R., Jiang, D., Xu, Z., Zhang, Y., Wu, Y., & Wang, X. (2023) · Nutrition Research Reviews · doi:10.1017/s0954422423000082 · Cited by 23
“It is characterised by low bone mass, degraded bone tissue and defective bone micro-architecture (42) .”
BackgroundSun, W., Xing, Y., Zhou, F., Ma, Y., Wan, X., & Ma, H. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s406849 · Cited by 19
“OC, β-CTX, and P1NP are the markers of bone metabolism and turnover recommended by IOF because they can reflect bone turnover and bone loss in patients.(19) Both osteoblasts and osteoclasts can express insulin receptors on their surfaces.”
BackgroundMethodOng, T. I. W., Lim, L., Chan, S. P., Chee, W. S. S., Ch’ng, A. S. H., Chong, E. G. M., Damodaran, P., Hew, F. L., Ibrahim, L., Khor, H. M., et al. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.06.002 · Cited by 23
“Reference was also made to the latest edition of other guidelines on the management of osteoporosis including the guidelines developed by the American Association of Clinical Endocrinologists/American College of Endocrinology [1], Bone Health and Osteoporosis Foundation [4], European Society for Clinical and Economic…”
MethodWu, X., Zhai, F., Chang, A., Wei, J., Guo, Y., & Zhang, J. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s406695 · Cited by 17
“The threshold levels for deficiency, insufficiency, and sufficiency of 25(OH)D were defined as follows: less than 12 ng/mL (30 nmol/L) for deficiency, between 12 and 30 ng/ mL (30 and 75 nmol/L) for insufficiency, and above 30 ng/mL (> 75 nmol/L) for sufficiency.(19) Furthermore, HOMA-IR was calculated using the follo…”
MethodFink, H. A., Butler, M. E., Claussen, A. M., Collins, E. S., Krohn, K., Taylor, B. C., Tikabo, S. S., Vang, D., Zerzan, N. L., & Ensrud, K. E. (2023) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4895 · Cited by 17
“(24,25) Thus, inaccuracy in fracture risk prediction tools that differs by race and ethnicity may lead to inequities in osteoporosis treatment.”
BackgroundA meta-analysis of the value of MRI-based VBQ scores for evaluating osteoporosis
Chen, A., Feng, S.-Y., Lai, L.-J., & Yan, C.-F. (2023) · Bone Reports · doi:10.1016/j.bonr.2023.101711 · Cited by 27
Marzban, M., Jamshidi, A., Khorrami, Z., Hall, M., Batty, J. A., Farhadi, A., Mahmudpour, M., Gholizade, M., Nabipour, I., Larijani, B. A., et al. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-04848-y · Cited by 18
Yılmaz, N., & Kösehasanoğulları, M. (2024) · Rheumatology International · doi:10.1007/s00296-024-05569-6 · Cited by 17
“Subsequently, they returned to the chair, and the elapsed time for the entire process was recorded [14].”
Ibrahim, N. ‘., Mohamed, N., Soelaiman, I. N., et al. (2015) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph121012958 · Cited by 17
Homeier, D. C. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.08.001 · Cited by 20
Müeller, D., & Gandjour, A. (2008) · Applied Health Economics and Health Policy · doi:10.1007/bf03256127 · Cited by 17
Chung, H.-Y., Chin, S. O., Kang, M.-I., Koh, J., Moon, S.-H., Yoon, B.-K., Yoon, H.-K., Chung, Y., & Park, H.-M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04041.x · Cited by 17
Yun-Kai, L., Hui, W., Zhu, X., Liang, G., & Zuo, J.-L. (2013) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.301.4264 · Cited by 18
Effects of combined ovariectomy with dexamethasone on rat lumbar vertebrae
Ren, H. J., Liang, D., Shen, G., Yao, Z., Jiang, X., Tang, J., Cui, J., & Lin, S. (2015) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000547 · Cited by 19
Yeap, S. S., Hew, F. L., Damodaran, P., Chee, W. S. S., Lee, J. K., Goh, E. M. L., Mumtaz, M., Lim, H. H., & Chan, S. P. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.02.004 · Cited by 22
Gonnelli, S., Caffarelli, C., Iolascon, G., Bertoldo, F., Mauro, G. L., Patti, A., & Nuti, R. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0681-8 · Cited by 17
Bastos, C. M., de Araújo, I. M., Nogueira‐Barbosa, M. H., Salmón, C. E. G., de Paula, F. J. A., & Troncon, L. E. A. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4014-3 · Cited by 19
Can denosumab be a substitute, competitor, or complement to bisphosphonates?
Kim, S. Y., Ok, H.-G., Birkenmaier, C., & Kim, K.-H. (2017) · The Korean journal of pain · doi:10.3344/kjp.2017.30.2.86 · Cited by 17
Ohashi, M., Hirano, T., Watanabe, K., Katsumi, K., Shoji, H., Mizouchi, T., & Endo, N. (2017) · Spine Deformity · doi:10.1016/j.jspd.2017.09.002 · Cited by 17
Fang, J., Franconeri, A., Boos, J., NiMhuircheartaigh, J., Zhang, Z., Brook, A., & Brook, O. R. (2018) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000744 · Cited by 17
Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis
Lewiecki, E. M., Bilezikian, J. P., Giangregorio, L., Greenspan, S. L., Khosla, S., Kostenuik, P. J., Krohn, K., McClung, M. R., Miller, P. D., & Pacifici, R. (2018) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2018.09.010 · Cited by 21
Self-citationYoo, K.-O., Kim, M., & Ly, S. Y. (2019) · Nutrition Research and Practice · doi:10.4162/nrp.2019.13.2.115 · Cited by 19
Parandeh, L., Shafaie, F. S., Malakouti, J., et al. (2019) · Women & Health · doi:10.1080/03630242.2019.1590495 · Cited by 17
Vrathasha, V., Weidner, H., & Nohe, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102500 · Cited by 19
Patient Preferences for Endometriosis Pain Treatments in the United States
Poulos, C. M., Soliman, A. M., Renz, C. L., Posner, J., & Agarwal, S. K. (2019) · Value in Health · doi:10.1016/j.jval.2018.12.010 · Cited by 21
IGF-1R/β-catenin signaling axis is involved in type 2 diabetic osteoporosis
Zhang, Z.-D., Ren, H. J., Wang, W., Shen, G., Huang, J., Zhan, M.-Q., Tang, J., Yu, X., Zhang, Y., Liang, D., et al. (2019) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1800648 · Cited by 18
Efficacy of Osteoporosis Prevention Smartphone App
Ryan, P. A., Brown, R., Csuka, M. E., & Papanek, P. E. (2019) · Nursing Research · doi:10.1097/nnr.0000000000000392 · Cited by 19
Effect of ANGPTL7 on Proliferation and Differentiation of MC3T3-E1 Cells
Lu, X., Lu, J., Zhang, L., & Xu, Y. (2019) · Medical Science Monitor · doi:10.12659/msm.918333 · Cited by 18
“Osteoporosis is a systemic and multifactorial disease that can occur in people of both sexes and at any age, but it is more common in postmenopausal women and older men [1,13].”
BackgroundSecondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Conley, R. B., Adib, G., Adler, R. A., Åkesson, K., Alexander, I. M., Amenta, K. C., Blank, R. D., Brox, W. T., Carmody, E. E., Chapman‐Novakofski, K., et al. (2020) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001743 · Cited by 21
“Unlike bisphosphonates, denosumab is not incorporated into the bone matrix and its antiresorptive effects do not continue after treatment is discontinued; rapid transition to another therapy after discontinuation of denosumab is recommended to prevent the risk of fractures from subsequently increasing.((64,151))”
BackgroundInfluentialLiu, S., Chen, R., Ding, N., Wang, Q., Huang, M., Liu, H., Xie, Z., Ou, Y., & Sheng, Z. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01315-4 · Cited by 18
Osteoporosis and Spine Surgery: A Critical Analysis Review
Diebo, B. G., Alshabab, B. S., Freilich, M., Shah, N. V., Redfern, J. A. I., Tarabichi, S., Shepherd, E. M., Lafage, R., Passias, P. G., Najjar, S., et al. (2020) · JBJS Reviews · doi:10.2106/jbjs.rvw.19.00160 · Cited by 21
Predictors of residual low back pain after acute osteoporotic compression fracture
Inose, H., Kato, T., Ichimura, S., Nakamura, H., Hoshino, M., Togawa, D., Hirano, T., Tokuhashi, Y., Ohba, T., Haro, H., et al. (2020) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2020.04.015 · Cited by 19
Nara, Y., Kitaura, H., Ogawa, S., Shen, W.-R., Qi, J., Ohori, F., Noguchi, T., Marahleh, A., Pramusita, A., Kinjo, R., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176120 · Cited by 19
Chen, J., Zheng, J., Chen, M., Lin, S., & Zhou, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695832 · Cited by 20
Liu, B., Liu, S., Wu, T., et al. (2021) · Orthopaedic Surgery · doi:10.1111/os.13133 · Cited by 17
Hadi, Y. B., Mann, R., Sohail, A. H., Shah-Khan, S. M., Szoka, N., Abunnaja, S., Tabone, L. E., Thakkar, S. J., & Singh, S. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.12.020 · Cited by 21
Osteoporosis: Epidemiology, Pathogenesis, Evaluation and Treatment
Chadha, M. D., Chaddha, R., Divakar, H., Kalyan, H. K., Seth, S., & Shah, P. (2022) · Open Journal of Orthopedics · doi:10.4236/ojo.2022.124016 · Cited by 25
Ensrud, K. E., Lui, L., Crandall, C. J., ORWOLL, E. S., Langsetmo, L., Schousboe, J. T., Fink, H. A., Lane, N. E., Kado, D. M., Cauley, J. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac324 · Cited by 19
“Several organizations (4-6) have endorsed osteoporosis screening with initial BMD testing in older men but have not addressed the timing of re-screening with repeat BMD measurement.”
BackgroundSri Lankan FRAX model and country-specific intervention thresholds
Lekamwasam, S. (2013) · Archives of Osteoporosis · doi:10.1007/s11657-013-0148-x · Cited by 17
Use of Renal Function Measurements for Assessing Fracture Risk in Postmenopausal Women
McCarthy, J. T., Rule, A. D., Achenbach, S. J., Bergstralh, E. J., Khosla, S., & Melton, L. J. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.11.1231 · Cited by 16
Geary, S., Selvi, F., Chuang, S. K., et al. (2014) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2014.11.008 · Cited by 17
Dhainaut, A., Hoff, M., Syversen, U., & Haugeberg, G. (2016) · Women s Health · doi:10.2217/whe.15.94 · Cited by 22
Inadequate Dietary Calcium and Vitamin D Intake in Patients with Osteoporotic Fracture
Yoon, D. S., Lee, Y., Ha, Y., et al. (2016) · Journal of Bone Metabolism · doi:10.11005/jbm.2016.23.2.55 · Cited by 17
Systematic scoping review of patients’ perceived needs of health services for osteoporosis
Chou, L., Shamdasani, P., Briggs, A. M., Cicuttini, F., Sullivan, K., Seneviwickrama, M., & Wluka, A. E. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4167-0 · Cited by 19
Chang, P.-Y., Feldman, D., Stefanick, M. L., McDonnell, D. P., Thompson, B. M., McDonald, J. G., & Lee, J. S. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3576 · Cited by 17
Gudmundsson, H. T., Hansen, K. E., Halldórsson, B. V., et al. (2019) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-019-0749-4 · Cited by 17
Iki, M., Yura, A., Fujita, Y., Kouda, K., Tachiki, T., Tamaki, J., Sato, Y., Moon, J., Hamada, M., Kajita, E., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115519 · Cited by 16
Management of osteoporosis in the aging male: Focus on zoledronic acid
Piper, P. K., & Gruntmanis, U. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4295 · Cited by 18
Bone Mineral Density Changes after Total Knee Replacement in Women Over the Age of 65
Hahn, M. H., & Won, Y. (2013) · Journal of Bone Metabolism · doi:10.11005/jbm.2013.20.2.105 · Cited by 18
Diagnosis and Classification of Vertebral Fracture
Griffith, J. F., Adams, J. E., & Genant, H. K. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch37 · Cited by 22
Hu, F., Li, X., Zhao, D. B., Chen, C., Liu, G., & Yang, Q. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07190-6 · Cited by 23
“According to the World Health Organization (WHO) definition of the DEXA criteria, osteopenia was defined as the lowest T-score of − 1.1 to − 2.4, and osteoporosis was defined as the lowest T-score ≤ − 2.5 [1, 17].”
InfluentialBinks, S. N. M., & Dobson, R. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0320-5 · Cited by 17
Contreras-Bolívar, V., Olveira, G., Porras, N., Acosta, E., Rubio‐Martín, E., Tapia, M. J., Abuín-Fernández, J., & Olveira, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-51069-0 · Cited by 16
Osteoporotic vertebral fractures: A diagnostic challenge in the 21st century
Capdevila-Reniu, A., Navarro-López, M., & López‐Soto, A. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.09.013 · Cited by 46
Operationalizing Treat-to-Target for Osteoporosis
Lewiecki, E. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.970 · Cited by 17
Self-citationBerry, T. M., & Moustafa, A. A. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.02.023 · Cited by 20
Min, C., Yoo, D. M., & Choi, H. G. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094437 · Cited by 20
Hormone therapy for postmenopausal osteoporosis management
Jiang, X., & Kagan, R. (2021) · Climacteric · doi:10.1080/13697137.2021.1957818 · Cited by 18
“More frequent BMD testing may be warranted in certain clinical situations [56].”
BackgroundEffect of Alkaline Drinking Water on Bone Density of Postmenopausal Women with Osteoporosis
Fasihi, S., Fazelian, S., Farahbod, F., Moradi, F., & Dehghan, M. (2021) · Journal of Menopausal Medicine · doi:10.6118/jmm.20036 · Cited by 21
“The BMD of a person can be compared with the mean BMD in healthy young adults with the same gender and race (T-score) or with the mean value of the BMD of his/her peers of the same race (Z-score, which is measured Dual-Energy X-ray absorptiometry (DXA, previously DEXA) or bone densitometry [25-28].”
BackgroundShahabi, S., Esfarjani, F., Reisi, J., Momenzadeh, S., Jami, M., & Zamani, S. (2021) · Advanced Biomedical Research · doi:10.4103/abr.abr_220_20 · Cited by 19
Evaluating Patients for Secondary Causes of Osteoporosis
Lewiecki, E. M. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00717-y · Cited by 20
Self-citationChen, Z., Liu, D., Xue Ming, T. A. N. G., Cui, Y. J., Hu, W., Regenstein, J. M., & Zhou, P. (2022) · Food Bioscience · doi:10.1016/j.fbio.2022.101572 · Cited by 18
Marycz, K., Kornicka‐Garbowska, K., Patej, A., Sobierajska, P., Kotela, A., Turlej, E., Kępska, M., Bieńko, A., & Wiglusz, R. J. (2022) · Materials · doi:10.3390/ma15062095 · Cited by 20
“Although OP is more common in Caucasians, women and elderly patients, numerous people of both sexes and all races suffer from it, and the number of osteoporotic patients is rapidly growing [1].”
BackgroundPredicting the Subsequent Contralateral Hip Fracture: Is FRAX the Answer?
Lott, A., Pflug, E. M., Parola, R., Egol, K. A., & Konda, S. R. (2022) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000002441 · Cited by 17
Frailty and Aging in HIV— Status Post 13 Years of National Awareness
Eke, U. A., Mohanty, K., Gruber‐Baldini, A. L., & Ryan, A. S. (2022) · The Journal of Frailty & Aging · doi:10.14283/jfa.2022.45 · Cited by 25
“Dietary supplementation and replacement of calcium, phosphate, and vitamin D are recommended in those patients with inadequate levels and treatment with bisphosphonates in those with osteoporosis, fragility fractures, and high FRAX scores (≥20%) (124, 128, 129).”
BackgroundLankester, J., Li, J., Salfati, E., Stefanick, M. L., Chan, K. H. K., Liu, S., Crandall, C. J., Clarke, S. L., & Assimes, T. L. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac215 · Cited by 18
Prevalence and risk factors of osteoporosis and osteopenia among residents in Hubei province, China
Zhang, L., Luo, X., Liu, H., Zhu, W., Zhang, X., Zhu, S., Zhang, X., Zhao, G., Li, T., Xiao, F., et al. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01245-7 · Cited by 19
Silva, D. D., Crous, A., & Abrahamse, H. (2023) · Regenerative Therapy · doi:10.1016/j.reth.2023.11.003 · Cited by 17
“However, these treatments potentially initiate rare and severe contra-indications when used for extended periods [6 e 8].”
BackgroundLi, D., Mao, S. S., & Budoff, M. J. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07040-5 · Cited by 19
“…Foundation (NOF) recommends BMD assessment for all women age 65 years and older and men age 70 years and older, regardless of clinical risk factors, as well as younger postmenopausal women, women in the menopausal transition, and men age 50 to 69 years with clinical risk factors for fracture [23].”
González-Quevedo, D., Rubia-Ortega, C., Sánchez-Delgado, A., Garceso, D. M., Sánchez-Siles, J.-M., Bardaji, M. F. B., Puerta, D. G. D. Q., & Tamimi, I. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02761-3 · Cited by 21
“…treatment was started on discharge according to the European guidance for diagnosis and management of osteoporosis, and the recommendations of the International Osteoporosis Foundation (IOF) [10, 11] and the Spanish Society of Rheumatology [12], which include calcium and vitamin D supplements.”
MethodSystemic Osteoporosis and Osteopenia Among Periprosthetic Fractures After Total Hip Arthroplasty
Seward, M. W., Hannon, C. P., Yuan, B. J., Kearns, A. E., Anderson, P. A., Berry, D. J., & Abdel, M. P. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2024.06.002 · Cited by 19
Denosumab: A novel antiresorptive drug for osteoporosis
Suresh, E., & Abrahamsen, B. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.13173 · Cited by 21
Rubin, K. H., Abrahamsen, B., Hermann, A. P., Bech, M., Gram, J., & Brixen, K. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811402412 · Cited by 17
Predictors of Osteoporosis Screening Completion Rates in a Primary Care Practice
DeJesus, R. S., Chaudhry, R., Angstman, K. B., et al. (2011) · Population Health Management · doi:10.1089/pop.2010.0057 · Cited by 16
Management of osteoporosis in elderly men
Gates, B. J., & Das, S. K. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.03.009 · Cited by 16
Calcaneal Bone Mineral Density in Young Adults Prescribed Selective Serotonin Reuptake Inhibitors
Seifert, C. F., & Wiltrout, T. R. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.423 · Cited by 19
Monaco, M. D., Castiglioni, C., Vallero, F., Monaco, R. D., & Tappero, R. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0088-y · Cited by 18
Osteoporosis Diagnosis and Management in Long-Term Care Facility
Aguilar, E. A., Barry, S., Cefalu, C. A., et al. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000562 · Cited by 16
Herrero, S., & Picó, Y. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.053 · Cited by 19
Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates
Gu, T., Lawrence, D. F. E., Stephenson, J. J., et al. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s97593 · Cited by 16
Nanduri, A. P., Fullman, S., Morell, L., Buyske, S. G., & Wagner, M. (2016) · Journal of Applied Gerontology · doi:10.1177/0733464816672045 · Cited by 18
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.